首页> 美国卫生研究院文献>Journal of the Boston Society of Medical Sciences >Regulation of endothelial VCAM-1 expression in murine cardiac grafts. Expression of allograft endothelial VCAM-1 can be manipulated with antagonist of IFN-alpha or IL-4 and is not required for allograft rejection.
【2h】

Regulation of endothelial VCAM-1 expression in murine cardiac grafts. Expression of allograft endothelial VCAM-1 can be manipulated with antagonist of IFN-alpha or IL-4 and is not required for allograft rejection.

机译:鼠心脏移植物中内皮VCAM-1表达的调节。异体移植血管内皮VCAM-1的表达可以用IFN-α或IL-4的拮抗剂来操纵并且对于异体移植排斥不是必需的。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

This report provides evidence to support the hypothesis that tumor necrosis factor-alpha (TNF-alpha) and IL-4 promote the expression of new endothelial surface molecules in rejecting murine heterotopic cardiac allografts. The microvascular endothelia of these cardiac allografts all develop strong reactivity with the monoclonal antibodies (mAbs) YN1.1/74 (anti-ICAM-1), M/K-2 (anti-VCAM-1) and MECA-32 (undefined molecule) within 3 to 5 days of graft implantation. Daily treatment of the allograft recipients with pentoxifylline (PTX), soluble TNF receptor (TNFR:Fc), anti-interleukin-4 (IL-4) mAb (11B11), or soluble IL-4 receptor, each abrogate the expression of endothelial VCAM-1 and reduce the endothelial reactivity with the mAbs YN1.1/74 and MECA-32 to levels found in cardiac isografts. This is accompanied by a reduction, but not an elimination, of interstitial leukocytic infiltration. Despite this, cardiac allograft recipients treated with PTX or the mAb 11B11 rejected allografts at the same rate as untreated allograft recipients, ie, within 10 to 12 days after graft implantation. These rejected grafts contained mRNAs for TNF-alpha and IL-4, as well as for all other cytokines that have been associated with rejecting allografts. This suggests that endothelial VCAM-1 expression, which is characteristic of rejection, is not an essential element of the rejection process. Interestingly, the grafts from the PTX-treated recipients continued to display rare, isolated VCAM-1 positive cells in the interstitium, which may be dendritic cells. In general, these studies demonstrate a role for IL-4 and TNF-alpha in the alterations of vascular endothelial phenotype observed in rejecting cardiac allografts. They also demonstrate that endothelial VCAM-1 expression is not essential for the allograft rejection process, and that the role of VCAM-1 in this process may be more subtle than was initially suspected.
机译:该报告提供了证据支持肿瘤坏死因子-α(TNF-alpha)和IL-4在排斥鼠异位心脏同种异体移植物中促进新的内皮表面分子表达的假说。这些心脏同种异体移植物的微血管内皮细胞都与单克隆抗体(mAb)YN1.1 / 74(抗ICAM-1),M / K-2(抗VCAM-1)和MECA-32(未定义分子)产生强反应性)在植入植入物的3到5天内。每天用己酮可可碱(PTX),可溶性TNF受体(TNFR:Fc),抗白介素4(IL-4)mAb(11B11)或可溶性IL-4受体治疗同种异体移植受体,每种都可消除内皮VCAM的表达-1并将其与mAb YN1.1 / 74和MECA-32的内皮反应性降低至心脏同种异体移植物中发现的水平。这伴随着间质白细胞浸润的减少而不是消除。尽管如此,用PTX或mAb 11B11治疗的心脏同种异体移植接受者以与未治疗的同种异体移植接受者相同的速率排斥异种移植,即移植后10到12天内。这些排斥的移植物含有TNF-α和IL-4以及与排斥同种异体移植物相关的所有其他细胞因子的mRNA。这表明,具有排斥作用的内皮VCAM-1表达不是排斥过程的基本要素。有趣的是,经过PTX处理的​​受体的移植物继续在间质中显示稀有的,分离的VCAM-1阳性细胞,该细胞可能是树突状细胞。总的来说,这些研究证明IL-4和TNF-α在排斥心脏同种异体移植物中观察到的血管内皮表型改变中具有作用。他们还证明,内皮VCAM-1表达对于同种异体排斥反应过程不是必需的,并且VCAM-1在该过程中的作用可能比最初怀疑的要微妙。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号